CIK 0001157601
- Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 267-824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $6,669,998
- in 2 filings, $6.7M under 10b5-1 plans
Net +$28,353,034. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise | +6,825 | $87.92 | $600K | 10,553 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise | +7,288 | $87.09 | $635K | 17,841 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −900 | $335.15 | $302K | 16,941 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,777 | $336.78 | $598K | 15,164 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,146 | $338.09 | $387K | 14,018 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −400 | $339.68 | $136K | 13,618 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,657 | $340.75 | $565K | 11,961 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,043 | $341.84 | $357K | 10,918 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,077 | $342.90 | $369K | 9,841 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −4,701 | $343.85 | $1.6M | 5,140 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,412 | $344.76 | $487K | 3,728 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Grant or award | +2,061 | 5,789 | ||
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise · Stock Option (Right to Buy) | −6,825 | 4,375 | ||
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise · Stock Option (Right to Buy) | −7,288 | 3,062 | ||
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Grant or award · Stock Option (Right to Buy) | +1,157 | 1,157 | ||
| 2025-02-28 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,052 | $340.99 | $359K | 3,903 |
| 2025-02-28 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −175 | $341.55 | $60K | 3,728 |
| 2025-01-24 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −103 | $335.24 | $35K | 4,955 |
| 2025-01-17 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −442 | $273.41 | $121K | 5,058 |
| 2024-06-14 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise | +1,900 | $87.09 | $165K | 7,400 |
Page 1 of 3 · 59 trades